ABSORB III Trial to test the Bioresorbable Vascular Scaffold (BVS)
ABSORB III will evaluate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with coronary artery disease (ischemic heart disease).
- Participants will be randomized to receive the Absorb BVS or XIENCE
- Study may last 1-5 years
- Myocardial ischemia (coronary artery disease)
- Candidate for coronary artery bypass graft (CABG) surgery
Can be done from home
KeywordsCoronary Artery Disease, ischemic heart disease, coronary heart disease, Myocardial ischemia, angina
Principal InvestigatorTheodore Bass, PROF & PRG DIR
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.